The DIVERSE Trials Act (H.R. 5030/S. 2706) could increase racial, socioeconomic and geographic diversity in clinical trials and make it easier for all cancer patients to participate.
Cancer Biomarker Testing
Advances in precision medicine have led to targeted cancer therapies that have improved patient outcomes and quality of life within populations of cancer patients with very specific biomarkers. Testing patients for cancer biomarkers is integral to identify those who may benefit from targeted therapy. Despite the importance of such testing, many cancer patients are not tested for biomarkers. This fact sheet highlights recent advancements in targeted cancer therapies and data from ACS CAN Survivor Views surveys of cancer patients and survivors assessing barriers to biomarker testing.